Late-Onset Pompe Disease: Comprehensive Disease-Characteristics Report

Executive summary

Late-onset Pompe disease (LOPD) is a rare, chronic, autosomal-recessive lysosomal glycogen-storage myopathy caused by biallelic pathogenic variants in GAA. Partial deficiency of lysosomal acid α-glucosidase causes glycogen accumulation, lysosomal expansion, blocked autophagic flux, metabolic stress, and progressive injury of skeletal and respiratory muscle. Unlike classic infantile Pompe disease, LOPD usually lacks severe hypertrophic cardiomyopathy. Its defining clinical problems are slowly progressive proximal/axial weakness and diaphragmatic respiratory insufficiency, which can occur independently of limb weakness. Diagnosis relies on low GAA activity—usually screened by dried blood spot—and confirmation by molecular testing and/or a second-tissue enzyme assay. Disease-modifying treatment is lifelong enzyme replacement therapy (ERT), supplemented by respiratory, rehabilitative, nutritional, orthopedic, and psychosocial care.

The most authoritative recent clinical source located was the November 2024 MetabERN pathway, developed using systematic review, AGREE II, and GRADE methods DOI/URL. Its central expert position is that Pompe care should be standardized, multidisciplinary, and initiated before irreversible muscle damage develops. (parenti2024theeuropeanreference pages 11-13, parenti2024theeuropeanreference pages 6-8, parenti2024theeuropeanreference pages 13-14)

Table: This compact table summarizes the most actionable disease-knowledge fields for late-onset Pompe disease, including genetics, core phenotypes, mechanisms, diagnostics, therapies, epidemiology, and models. It is designed for rapid knowledge-base curation with conservative ontology suggestions and evidence-linked claims.

1. Disease information

Definition and category. LOPD is the attenuated juvenile/adult spectrum of Pompe disease, a Mendelian lysosomal storage disorder, glycogen storage disease, metabolic myopathy, and autophagic myopathy. Common names are glycogen storage disease type II, acid maltase deficiency, acid α-glucosidase deficiency, non-classic Pompe disease, juvenile-onset Pompe disease, and adult-onset Pompe disease. LOPD is generally defined by onset after infancy and residual enzyme activity; boundaries based on age vary among publications. (aguilargonzalez2022isogenicgaakomurine pages 1-2, ozdamar2023expertopinionon pages 1-2)

Identifiers. Pompe disease is OMIM 232300. Appropriate disease-level mappings include MeSH Pompe Disease, Orphanet Pompe disease, and ICD-10-CM E74.02 (Pompe disease). ICD-11 places Pompe disease under glycogen-storage disorders. The exact LOPD-specific MONDO identifier was not verified in the retrieved evidence and should be resolved directly against the current MONDO release rather than inferred. The evidence summarized here is aggregated from guidelines, cohorts, trials, and disease registries—not individual EHR records.

A concise abstract statement from the 2023 review is: “Pompe disease … is an autosomal recessive disorder caused by mutations in the GAA gene.” Published August 2023; DOI/URL. (labella2023acomprehensiveupdate pages 8-10)

2. Etiology, risk, protection, and gene–environment interaction

The necessary cause is biallelic germline GAA dysfunction. GAA, at chromosome 17q25, encodes lysosomal acid α-glucosidase, which hydrolyzes α-1,4 and α-1,6 glycogen linkages. LOPD commonly retains approximately 2–40% assay-dependent residual activity, versus <1% in classic infantile disease; residual activity broadly predicts phenotype but does not completely explain expressivity. (moschetti2024mutationspectrumof pages 1-2, parenti2024theeuropeanreference pages 6-8)

The major “risk factors” are therefore two pathogenic parental alleles, family history, ancestry-associated founder/common alleles, and consanguinity. The European splice variant NM_000152.5:c.-32-13T>G is particularly common in affected White populations and permits some correctly spliced transcript. In one 18-person LOPD cohort it occurred in 16/18 patients. More than 900 disease-associated GAA variants have been catalogued across missense, nonsense, frameshift, splice, indel, and larger rearrangement classes. (alandydy2019variableclinicalfeatures pages 1-2, moschetti2024mutationspectrumof pages 1-2)

No toxin, infection, smoking behavior, diet, occupation, or radiation exposure is an established primary cause. Exercise, nutrition, intercurrent infection, and respiratory care can alter function or complications but do not determine whether genetically susceptible individuals have Pompe disease. No validated protective GAA allele, environmental prevention, or reproducible disease-modifier gene is established for routine clinical use. Exercise-gene polymorphisms and other modifiers remain investigational. Gene–environment interaction evidence is therefore limited chiefly to how activity, nutrition, aging, infection, and treatment interact with a fixed enzymatic defect.

3. Phenotypes and quality of life

LOPD is heterogeneous and insidious. Core manifestations are:

• Proximal lower-limb and limb-girdle weakness (HP:0003701/HP:0003325), difficulty climbing stairs or rising from a chair, waddling gait, and exercise intolerance (HP:0003546).
• Axial/paraspinal weakness (HP:0003327), lumbar hyperlordosis, scapular winging, scoliosis (HP:0002650), and later contractures.
• Respiratory-muscle and diaphragmatic weakness, restrictive ventilatory defect (HP:0002091), orthopnea/dyspnea, impaired cough, sleep-disordered breathing or sleep apnea (HP:0010535), morning headache, recurrent infection, and respiratory failure (HP:0002093). Respiratory dysfunction may precede conspicuous limb weakness and is the principal cause of morbidity and mortality. (ozdamar2023expertopinionon pages 3-4, ozdamar2023expertopinionon pages 2-3, ozdamar2023expertopinionon pages 1-2)
• Laboratory abnormalities: CK may be normal or elevated—sometimes up to 15-fold—while AST/ALT can be mildly elevated. Normal CK does not exclude disease. (ozdamar2023expertopinionon pages 3-4, labella2023acomprehensiveupdate pages 8-10)
• Other multisystem findings: fatigue (HP:0012378), myalgia (HP:0003326), dysphagia (HP:0002015), feeding/nutritional difficulties, low bone density/osteoporosis (HP:0000939), and occasional hearing, gastrointestinal, urinary, or cerebrovascular abnormalities. Intracranial aneurysm and vertebrobasilar dolichoectasia have been reported, but their population frequency and screening yield remain uncertain. Cardiac disease is usually absent or mild, although occasional cardiomyopathy occurs. (alandydy2019variableclinicalfeatures pages 1-2, parenti2024theeuropeanreference pages 11-13)

Severity ranges from asymptomatic hyperCKemia to wheelchair and ventilator dependence. In one small cohort, 12/18 used BiPAP, 5/18 had scoliosis, 3/18 cardiomyopathy, and 2/18 cerebral aneurysm; these are descriptive referral-cohort frequencies, not generalizable prevalence estimates. (alandydy2019variableclinicalfeatures pages 1-2)

LOPD impairs mobility, self-care, work, social participation, fatigue, and emotional well-being. PROMIS, EQ-5D-5L, Rasch-built Pompe-specific Activity, and Subject’s Global Impression of Change are relevant instruments. In PROPEL, 90% receiving cipaglucosidase alfa plus miglustat versus 59% receiving alglucosidase/placebo were responders for perceived ability to move around at week 52 (P=0.0005). (byrne2024longtermsafetyand pages 1-2)

4. Genetic and molecular information

Causal gene: GAA; germline, autosomal recessive, loss-of-function. Variants may reduce transcription/splicing, folding, lysosomal trafficking, proteolytic maturation, or catalytic activity. The phenotype reflects the combined residual function of both alleles, but genotype–phenotype correlation is imperfect. In a 2024 Italian screen of 2,934 symptomatic referrals, 39 had low enzyme activity plus two causal variants and 22 carried variants of uncertain significance. (moschetti2024mutationspectrumof pages 2-3, moschetti2024mutationspectrumof pages 3-5)

Variant interpretation should follow ACMG/AMP and ClinGen Lysosomal Diseases Variant Curation Expert Panel specifications. Pseudodeficiency alleles lower activity against artificial substrates without causing Pompe disease. c.271G>A (p.Asp91Asn) was classified as benign in the cited analysis; overcalling it can produce inappropriate ERT and obscure another diagnosis. Sequence analysis should be supplemented by deletion/duplication analysis if two explanatory alleles are not found; RNA studies can resolve cryptic splice variants. Allele frequencies must be checked variant-by-variant in current gnomAD/ClinVar releases. (giliberto2024frompastto pages 12-15)

No recurrent aneuploidy, translocation, repeat expansion, mitochondrial-DNA defect, or somatic driver defines LOPD. CMA, karyotyping, FISH, and repeat-expansion testing are not first-line tests. Disease-specific epigenetic alterations are not validated diagnostic or prognostic markers.

5. Environmental information

Environmental, infectious, and lifestyle causes are not applicable as primary etiology. Respiratory infections can precipitate decompensation; immobility aggravates deconditioning, osteoporosis, and contractures. Carefully prescribed aerobic and resistance activity, adequate protein/energy intake, vaccination, airway clearance, and avoidance of prolonged inactivity support health but do not correct GAA deficiency.

6. Mechanism and pathophysiology

The causal chain is:

biallelic GAA loss → deficient lysosomal glycogen hydrolysis → glycogen-filled/swollen lysosomes → lysosomal rupture/trafficking disturbance and failed autophagosome–lysosome fusion → autophagic debris, p62/SQSTM1 and ubiquitinated-protein accumulation → AMPK activation, reduced mTORC1 signaling, altered TFEB activity, oxidative stress and mitochondrial dysfunction → myofibrillar disorganization, apoptosis/regeneration, weakness and respiratory failure. (monceau2024decodingthemuscle pages 1-2, do2024failureofautophagy pages 7-8, do2024failureofautophagy pages 5-7, do2024failureofautophagy pages 4-5)

Autophagic lesions in adult muscle may exceed the apparent lysosomal enlargement; biopsies show autophagic vacuoles in approximately 30–40% of fibers, and buildup can occupy up to 40% of fiber volume in knockout mice. Type II myofibers are particularly affected in models. Autophagic debris also impedes recombinant-enzyme delivery, helping explain incomplete skeletal-muscle response. TFEB overexpression or experimental mTORC1 restoration can reverse buildup in model systems, but neither is established human therapy. Suggested annotations include GO glycogen catabolic process, macroautophagy, lysosome organization, response to oxidative stress, and GO cellular components lysosome and autophagosome. Principal CL mapping is skeletal muscle cell/myofiber; macrophages and regenerative myogenic cells are downstream participants. (do2024failureofautophagy pages 7-8, do2024failureofautophagy pages 5-7, do2024failureofautophagy pages 4-5)

Recent multi-omics. A 2024 study applied single-nucleus RNA-seq to biopsies from eight LOPD patients and four matched controls and spatially compared normal, non-vacuolated, and vacuolated fibers. Early non-vacuolated fibers had reduced glycolysis with increased lipid/amino-acid metabolism; affected tissue showed more slow/regenerative fibers and macrophages, autophagy upregulation, reduced ribosomal/mitochondrial programs, and defective oxidative phosphorylation. Inflammation, apoptosis, and regeneration were concentrated in vacuolated fibers. Published July 2024; DOI/URL. (monceau2024decodingthemuscle pages 1-2, monceau2024decodingthemuscle pages 2-3)

Proteomics identified 178 altered muscle proteins, of which only 47 normalized after one year of ERT; oxidative metabolism, contractile regulation, cytoskeletal remodeling, ER stress, unfolded-protein response, and lysosomal-tethering abnormalities persisted. Published March 2021; DOI/URL. (moriggi2021muscleproteomicprofile pages 1-2, moriggi2021muscleproteomicprofile pages 16-17)

7. Anatomical structures

Primary involvement is bilateral, generally symmetric skeletal muscle: pelvic-girdle, hip extensors, thigh, paraspinal/axial, abdominal-wall, diaphragm, and intercostal muscles. Respiratory muscle involvement may be disproportionate. Secondary targets include bulbar/swallowing musculature, bone, smooth muscle, and cerebral arterial walls. The relevant subcellular compartments are lysosome, autophagosome, mitochondrion, ER, and cytosol. Suggested UBERON mappings include skeletal muscle tissue, diaphragm, abdominal muscle, paraspinal muscle, respiratory system, and cerebral artery. (parenti2024theeuropeanreference pages 11-13, labella2023acomprehensiveupdate pages 8-10)

8. Temporal development

Onset may occur from childhood through late adulthood and is usually chronic and insidious. Disease is lifelong, variably progressive, and does not spontaneously remit. Diagnostic delay is commonly 5–30 years, and nearly one-third of patients may initially receive another diagnosis. Untreated natural-history summaries report detectable FVC deterioration within approximately two years and 6-minute-walk deterioration over longer intervals, around nine years, although individual trajectories vary greatly. Early treatment is the main modifiable prognostic opportunity because established fatty replacement and autophagic destruction are incompletely reversible. (ozdamar2023expertopinionon pages 3-4, ozdamar2023expertopinionon pages 4-6)

9. Inheritance and population

Inheritance is autosomal recessive: each pregnancy of two heterozygous carriers has a 25% affected, 50% carrier, and 25% unaffected/non-carrier probability. Penetrance for genuinely pathogenic biallelic genotypes is high but age-dependent; expressivity is markedly variable. Anticipation is not recognized. Germline mosaicism is theoretically possible but not a characteristic feature.

Frequently cited overall Pompe prevalence is approximately 1:40,000–1:57,000, but newborn sequencing estimates suggest underdiagnosis and marked ancestry variation. Population-database modeling estimated carrier frequencies of 1.7% in Koreans and 0.7% in Japanese, corresponding to predicted genetic prevalences of 1:13,657 and 1:78,013; such predictions include uncertainty from penetrance and variant classification. Both sexes are affected approximately equally. (alandydy2019variableclinicalfeatures pages 1-2, aguilargonzalez2022isogenicgaakomurine pages 1-2)

10. Diagnostics and screening

Recommended pathway: recognize unexplained proximal/axial weakness, diaphragmatic restriction, exercise intolerance, or hyperCKemia → dried-blood-spot GAA assay → confirm low activity in leukocytes, fibroblasts, or muscle and identify two pathogenic/likely pathogenic GAA alleles. A second independent method is important because sample quality and pseudodeficiency can cause false positives. (ozdamar2023expertopinionon pages 3-4, ozdamar2023expertopinionon pages 1-2)

Assess CK, AST/ALT, urinary Glc4/Hex4, seated and supine FVC, maximal inspiratory/expiratory pressures, sleep study/oximetry, cough flow, MRC strength, dynamometry, timed tests, and 6MWT. A >25% seated-to-supine FVC fall suggests diaphragmatic weakness. EMG may show myopathy and paraspinal myotonic discharges without clinical myotonia. MRI characteristically identifies paraspinal, abdominal, and hip-extensor involvement. Biopsy—now reserved for unresolved cases—shows PAS-positive, acid-phosphatase-positive glycogen vacuoles and autophagic pathology. (ozdamar2023expertopinionon pages 3-4, labella2023acomprehensiveupdate pages 8-10)

Potential monitoring biomarkers include urinary Glc4/Hex4, CK, BNP/pro-BNP where cardiac disease is suspected, vacuolated PAS-positive lymphocytes, miR-1-3p/miR-133a-3p/miR-206, and neurofilament light; none replaces clinical respiratory and motor assessment. (parenti2024theeuropeanreference pages 6-8, labella2023acomprehensiveupdate pages 21-22)

Differentials include limb-girdle muscular dystrophy, inflammatory or mitochondrial myopathy, other glycogenoses, spinal muscular disease, congenital myopathy, Danon disease, and oculopharyngeal muscular dystrophy. Normal CK, EMG, or biopsy does not exclude LOPD. (giliberto2024frompastto pages 12-15, ozdamar2023expertopinionon pages 3-4, parenti2024theeuropeanreference pages 11-13)

WES/WGS or neuromuscular panels are useful when phenotype is atypical or single-gene analysis is incomplete; RNA sequencing can establish splice effects. Newborn screening, presymptomatic sibling testing, carrier/cascade screening, prenatal diagnosis, and preimplantation genetic testing are technically feasible after familial variants are known.

11. Outcome and prognosis

Respiratory insufficiency, infection, and progressive neuromuscular disability dominate morbidity and mortality. Adult survival is reduced, but robust contemporary 5- or 10-year survival percentages are not established because of rarity, phenotypic heterogeneity, and treatment-era change. Prognosis is better with earlier diagnosis, greater baseline motor/FVC reserve, lower fixed fatty replacement, and sustained treatment. ERT generally improves or stabilizes function initially but does not reliably reverse advanced disease; many patients plateau after two to three years and subsequently decline. (byrne2024longtermsafetyand pages 1-2, labella2023acomprehensiveupdate pages 11-12)

12. Treatment and real-world implementation

• Alglucosidase alfa: recombinant human GAA, 20 mg/kg IV every two weeks; first approved in 2006. The 90-person LOTS trial improved/stabilized 6MWD and percent-predicted FVC. Infusion reactions and anti-drug antibodies occur; skeletal-muscle uptake and durability are limited. (labella2023acomprehensiveupdate pages 11-12, parenti2024theeuropeanreference pages 13-14)
• Avalglucosidase alfa: second-generation rhGAA enriched for mannose-6-phosphate receptor targeting, 20 mg/kg every two weeks. COMET established non-inferiority to alglucosidase; an expert summary reported week-49 FVC gains of 2.89 versus 0.46 percentage points, without statistically confirmed superiority. FDA approval was in 2021 and EMA approval in 2022. (ozdamar2023expertopinionon pages 4-6, labella2023acomprehensiveupdate pages 11-12)
• Cipaglucosidase alfa plus miglustat: high-M6P rhGAA plus an oral enzyme stabilizer. A phase I/II regimen used cipaglucosidase 20 mg/kg IV plus miglustat 260 mg orally every two weeks. At up to 48 months, ambulatory ERT-experienced patients maintained approximately 5–6% predicted 6MWD improvement, while ERT-naïve patients had approximately 10–12%; FVC was stable in experienced patients and improved 3–8% in the small naïve cohort. CK and Hex4 improved, with safety resembling alglucosidase. EMA approval occurred in 2023; subsequent US approval applies to selected adults inadequately responding to current ERT. Published December 2024; DOI/URL. (byrne2024longtermsafetyand pages 1-2, parenti2024theeuropeanreference pages 13-14)

Suggested NCIT intervention concepts are enzyme replacement therapy, alglucosidase alfa, avalglucosidase alfa, cipaglucosidase alfa, miglustat, noninvasive ventilation, physical therapy, and gene therapy; exact codes should be validated against the current NCIT release.

Supportive management includes individualized submaximal aerobic/resistance therapy without overwork injury, stretching and contracture prevention, mobility aids, noninvasive ventilation, airway-clearance/cough-assist techniques, vaccination, prompt infection treatment, swallowing and nutritional assessment, bone-health care, occupational therapy, and psychosocial support. ERT should begin promptly in symptomatic patients and in presymptomatic patients with objective weakness or respiratory abnormality; clinically silent individuals require approximately six-month surveillance. (ozdamar2023expertopinionon pages 4-6, parenti2024theeuropeanreference pages 11-13)

Experimental therapy. RESOLUTE (NCT04093349) is an active-not-recruiting phase 1/2 dose-escalation study of AAV vector SPK-3006 in adults previously treated with ERT; four participants were enrolled, with five-year safety and immune follow-up. ClinicalTrials.gov. Gene therapy’s goals are sustained endogenous GAA secretion and cross-correction, but capsid immunity, transgene immunity, dose toxicity, durability, and skeletal-muscle delivery remain unresolved. (NCT04093349 chunk 1)

13. Prevention

There is no vaccine, exposure avoidance, or lifestyle intervention that prevents the genetic disease. Primary genetic prevention/options include carrier testing, genetic counseling, prenatal diagnosis, and preimplantation genetic testing. Secondary prevention comprises newborn/cascade screening and treatment before irreversible weakness. Tertiary prevention includes ERT, respiratory surveillance/support, vaccination, airway clearance, safe exercise, fall/contracture prevention, bone care, and nutrition. Each sibling of an affected individual should receive targeted familial-variant and/or enzyme testing.

14. Natural disease in other species

Pompe-like natural GAA deficiency has been described in Japanese quail (Coturnix japonica, NCBI Taxon 93934), with additional spontaneous glycogen-storage models reported across domestic species. It is inherited/metabolic, not transmissible or zoonotic. Comparative pathology includes lysosomal glycogen storage and muscle dysfunction, although species differ in severity, cardiac involvement, and treatment response. (aguilargonzalez2022isogenicgaakomurine pages 1-2)

15. Model organisms

The principal model is the Gaa-knockout mouse (Mus musculus, Taxon 10090), which reproduces absent enzyme, skeletal/cardiac glycogen storage, weakness, autophagic buildup, and impaired ERT delivery. Its limitations are severe/null-genotype biology, strain-dependent phenotype, and imperfect modeling of decades-long human LOPD. Japanese quail offers a natural model. CRISPR-generated GAA-knockout murine myotubes reproduce absent activity, glycogen excess, increased autophagy, and reduced cation-independent mannose-6-phosphate receptor and support ERT/gene-therapy screening. Human fibroblasts, primary myoblasts, and patient-derived iPSC muscle systems provide genotype-specific in-vitro models but incompletely reproduce mature muscle architecture and systemic respiratory disease. (aguilargonzalez2022isogenicgaakomurine pages 1-2, do2024failureofautophagy pages 7-8)

Evidence limitations

Phenotype percentages are highly cohort-dependent; several manifestations lack population-level frequency estimates. Variant frequencies and ontology identifiers should be revalidated against live ClinVar, gnomAD, HPO, MONDO, UBERON, GO, CL, CHEBI, and NCIT releases before database ingestion. Most retrieved sources reported DOI rather than PMID metadata; therefore, DOI-linked primary papers are supplied rather than inventing unverified PMIDs. The strongest 2023–2024 evidence comprises expert pathways/reviews, small rare-disease cohorts, and extension studies; comparative long-term effectiveness among newer ERTs remains uncertain without direct head-to-head trials.

References

1. (parenti2024theeuropeanreference pages 11-13): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

2. (parenti2024theeuropeanreference pages 6-8): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

3. (parenti2024theeuropeanreference pages 13-14): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

4. (labella2023acomprehensiveupdate pages 8-10): Beatrice Labella, Stefano Cotti Piccinelli, Barbara Risi, Filomena Caria, Simona Damioli, Enrica Bertella, Loris Poli, Alessandro Padovani, and Massimiliano Filosto. A comprehensive update on late-onset pompe disease. Biomolecules, 13:1279, Aug 2023. URL: https://doi.org/10.3390/biom13091279, doi:10.3390/biom13091279. This article has 76 citations.

5. (ozdamar2023expertopinionon pages 1-2): Sevim Erdem Ozdamar, Ayse Filiz Koc, Hacer Durmus Tekce, Dilcan Kotan, Ahmet Hakan Ekmekci, Ihsan Sukru Sengun, Ayse Nur Yuceyar, and Kayihan Uluc. Expert opinion on the diagnostic odyssey and management of late-onset pompe disease: a neurologist's perspective. Frontiers in Neurology, May 2023. URL: https://doi.org/10.3389/fneur.2023.1095134, doi:10.3389/fneur.2023.1095134. This article has 14 citations and is from a peer-reviewed journal.

6. (ozdamar2023expertopinionon pages 4-6): Sevim Erdem Ozdamar, Ayse Filiz Koc, Hacer Durmus Tekce, Dilcan Kotan, Ahmet Hakan Ekmekci, Ihsan Sukru Sengun, Ayse Nur Yuceyar, and Kayihan Uluc. Expert opinion on the diagnostic odyssey and management of late-onset pompe disease: a neurologist's perspective. Frontiers in Neurology, May 2023. URL: https://doi.org/10.3389/fneur.2023.1095134, doi:10.3389/fneur.2023.1095134. This article has 14 citations and is from a peer-reviewed journal.

7. (alandydy2019variableclinicalfeatures pages 1-2): Jousef Alandy-dy, Marie Wencel, Kathy Hall, Julie Simon, Yanjun Chen, Erik Valenti, Jade Yang, Deeksha Bali, Anita Lakatos, Namita Goyal, Tahseen Mozaffar, and Virginia Kimonis. Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset pompe disease. Annals of Translational Medicine, 7:276-276, Jul 2019. URL: https://doi.org/10.21037/atm.2019.06.48, doi:10.21037/atm.2019.06.48. This article has 25 citations.

8. (moschetti2024mutationspectrumof pages 1-2): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

9. (giliberto2024frompastto pages 12-15): F. Giliberto, P. Buonfiglio, Gabriel Capellino, C. L. Massini, Viviana Dalamón, L. Luce, M. Carcione, C. M. –. Roentgen, and Prof. PhD. Florencia Giliberto. From past to present: pompe disease, pseudodeficiency alleles, and diagnostic challenges. MedRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.03.24314698, doi:10.1101/2024.10.03.24314698. This article has 0 citations.

10. (ozdamar2023expertopinionon pages 3-4): Sevim Erdem Ozdamar, Ayse Filiz Koc, Hacer Durmus Tekce, Dilcan Kotan, Ahmet Hakan Ekmekci, Ihsan Sukru Sengun, Ayse Nur Yuceyar, and Kayihan Uluc. Expert opinion on the diagnostic odyssey and management of late-onset pompe disease: a neurologist's perspective. Frontiers in Neurology, May 2023. URL: https://doi.org/10.3389/fneur.2023.1095134, doi:10.3389/fneur.2023.1095134. This article has 14 citations and is from a peer-reviewed journal.

11. (ozdamar2023expertopinionon pages 2-3): Sevim Erdem Ozdamar, Ayse Filiz Koc, Hacer Durmus Tekce, Dilcan Kotan, Ahmet Hakan Ekmekci, Ihsan Sukru Sengun, Ayse Nur Yuceyar, and Kayihan Uluc. Expert opinion on the diagnostic odyssey and management of late-onset pompe disease: a neurologist's perspective. Frontiers in Neurology, May 2023. URL: https://doi.org/10.3389/fneur.2023.1095134, doi:10.3389/fneur.2023.1095134. This article has 14 citations and is from a peer-reviewed journal.

12. (monceau2024decodingthemuscle pages 1-2): Alexandra Monceau, Rasya Gokul Nath, Xavier Suárez-Calvet, Olimpia Musumeci, Antonio Toscano, Biruta Kierdaszuk, Anna Kostera-Pruszczyk, Cristina Domínguez-González, Aurelio Hernández-Lain, Carmen Paradas, Eloy Rivas, George Papadimas, Constantinos Papadopoulos, Margarita Chrysanthou-Piterou, Eduard Gallardo, Montse Olivé, James Lilleker, Mark E Roberts, Domenica Marchese, Giulia Lunazzi, Holger Heyn, Esther Fernández-Simón, Elisa Villalobos, James Clark, Panos Katsikis, Catherine Collins, Priyanka Mehra, Zoe Laidler, Amy Vincent, Giorgio Tasca, Chiara Marini-Bettolo, Michela Guglieri, Volker Straub, Nina Raben, and Jordi Díaz-Manera. Decoding the muscle transcriptome of patients with late-onset pompe disease reveals markers of disease progression. Brain, 147:4213-4226, Jul 2024. URL: https://doi.org/10.1093/brain/awae249, doi:10.1093/brain/awae249. This article has 9 citations and is from a highest quality peer-reviewed journal.

13. (do2024failureofautophagy pages 7-8): Hung Do, Naresh K. Meena, and Nina Raben. Failure of autophagy in pompe disease. May 2024. URL: https://doi.org/10.3390/biom14050573, doi:10.3390/biom14050573. This article has 17 citations.

14. (do2024failureofautophagy pages 4-5): Hung Do, Naresh K. Meena, and Nina Raben. Failure of autophagy in pompe disease. May 2024. URL: https://doi.org/10.3390/biom14050573, doi:10.3390/biom14050573. This article has 17 citations.

15. (monceau2024decodingthemuscle pages 2-3): Alexandra Monceau, Rasya Gokul Nath, Xavier Suárez-Calvet, Olimpia Musumeci, Antonio Toscano, Biruta Kierdaszuk, Anna Kostera-Pruszczyk, Cristina Domínguez-González, Aurelio Hernández-Lain, Carmen Paradas, Eloy Rivas, George Papadimas, Constantinos Papadopoulos, Margarita Chrysanthou-Piterou, Eduard Gallardo, Montse Olivé, James Lilleker, Mark E Roberts, Domenica Marchese, Giulia Lunazzi, Holger Heyn, Esther Fernández-Simón, Elisa Villalobos, James Clark, Panos Katsikis, Catherine Collins, Priyanka Mehra, Zoe Laidler, Amy Vincent, Giorgio Tasca, Chiara Marini-Bettolo, Michela Guglieri, Volker Straub, Nina Raben, and Jordi Díaz-Manera. Decoding the muscle transcriptome of patients with late-onset pompe disease reveals markers of disease progression. Brain, 147:4213-4226, Jul 2024. URL: https://doi.org/10.1093/brain/awae249, doi:10.1093/brain/awae249. This article has 9 citations and is from a highest quality peer-reviewed journal.

16. (moriggi2021muscleproteomicprofile pages 1-2): Manuela Moriggi, Daniele Capitanio, Enrica Torretta, Pietro Barbacini, Cinzia Bragato, Patrizia Sartori, Maurizio Moggio, Lorenzo Maggi, Marina Mora, and Cecilia Gelfi. Muscle proteomic profile before and after enzyme replacement therapy in late-onset pompe disease. International Journal of Molecular Sciences, 22:2850, Mar 2021. URL: https://doi.org/10.3390/ijms22062850, doi:10.3390/ijms22062850. This article has 19 citations.

17. (do2024failureofautophagy pages 5-7): Hung Do, Naresh K. Meena, and Nina Raben. Failure of autophagy in pompe disease. May 2024. URL: https://doi.org/10.3390/biom14050573, doi:10.3390/biom14050573. This article has 17 citations.

18. (labella2023acomprehensiveupdate pages 21-22): Beatrice Labella, Stefano Cotti Piccinelli, Barbara Risi, Filomena Caria, Simona Damioli, Enrica Bertella, Loris Poli, Alessandro Padovani, and Massimiliano Filosto. A comprehensive update on late-onset pompe disease. Biomolecules, 13:1279, Aug 2023. URL: https://doi.org/10.3390/biom13091279, doi:10.3390/biom13091279. This article has 76 citations.

19. (byrne2024longtermsafetyand pages 1-2): Barry J. Byrne, Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Paula R. Clemens, Ozlem Goker-Alpan, Xue Ming, Mark Roberts, Matthias Vorgerd, Kumaraswamy Sivakumar, Ans T. van der Ploeg, Mitchell Goldman, Jacquelyn Wright, Fred Holdbrook, Vipul Jain, Elfrida R. Benjamin, Franklin Johnson, Sheela Sitaraman Das, Yasmine Wasfi, and Tahseen Mozaffar. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with pompe disease: an open-label phase i/ii study (atb200-02). Journal of Neurology, 271:1787-1801, Dec 2024. URL: https://doi.org/10.1007/s00415-023-12096-0, doi:10.1007/s00415-023-12096-0. This article has 24 citations and is from a domain leading peer-reviewed journal.

20. (sharshakova2026pompediseasepathogenesis pages 1-2): Alexandra Sharshakova, Alisa Fattakhova, Valeriya Solovyeva, Albert Sufianov, Galina Sufianova, Grigorii Kutovoi, and Albert Rizvanov. Pompe disease: pathogenesis, molecular mechanisms, neurological aspects, diagnostics and modern therapeutic approaches. International Journal of Molecular Sciences, 27:3703, Apr 2026. URL: https://doi.org/10.3390/ijms27083703, doi:10.3390/ijms27083703. This article has 1 citations.

21. (aguilargonzalez2022isogenicgaakomurine pages 1-2): Araceli Aguilar-González, Juan Elías González-Correa, Eliana Barriocanal-Casado, Iris Ramos-Hernández, Miguel A. Lerma-Juárez, Sara Greco, Juan José Rodríguez-Sevilla, Francisco Javier Molina-Estévez, Valle Montalvo-Romeral, Giuseppe Ronzitti, Rosario María Sánchez-Martín, Francisco Martín, and Pilar Muñoz. Isogenic gaa-ko murine muscle cell lines mimicking severe pompe mutations as preclinical models for the screening of potential gene therapy strategies. International Journal of Molecular Sciences, 23:6298, Jun 2022. URL: https://doi.org/10.3390/ijms23116298, doi:10.3390/ijms23116298. This article has 5 citations.

22. (labella2023acomprehensiveupdate pages 11-12): Beatrice Labella, Stefano Cotti Piccinelli, Barbara Risi, Filomena Caria, Simona Damioli, Enrica Bertella, Loris Poli, Alessandro Padovani, and Massimiliano Filosto. A comprehensive update on late-onset pompe disease. Biomolecules, 13:1279, Aug 2023. URL: https://doi.org/10.3390/biom13091279, doi:10.3390/biom13091279. This article has 76 citations.

23. (NCT04093349 chunk 1): A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE). Spark Therapeutics, Inc.. 2020. ClinicalTrials.gov Identifier: NCT04093349

24. (NCT07123155 chunk 1): Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD). Shionogi. 2025. ClinicalTrials.gov Identifier: NCT07123155

25. (NCT07750990 chunk 1): An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD). Shionogi. 2026. ClinicalTrials.gov Identifier: NCT07750990

26. (moschetti2024mutationspectrumof pages 2-3): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

27. (moschetti2024mutationspectrumof pages 3-5): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

28. (moriggi2021muscleproteomicprofile pages 16-17): Manuela Moriggi, Daniele Capitanio, Enrica Torretta, Pietro Barbacini, Cinzia Bragato, Patrizia Sartori, Maurizio Moggio, Lorenzo Maggi, Marina Mora, and Cecilia Gelfi. Muscle proteomic profile before and after enzyme replacement therapy in late-onset pompe disease. International Journal of Molecular Sciences, 22:2850, Mar 2021. URL: https://doi.org/10.3390/ijms22062850, doi:10.3390/ijms22062850. This article has 19 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.